Literature DB >> 22674979

Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, β-catenin, and SMAR1 to repress HIV transcription.

Lisa J Henderson1, Srinivas D Narasipura, Vyacheslav Adarichev, Fatah Kashanchi, Lena Al-Harthi.   

Abstract

Molecular regulation of HIV transcription is a multifaceted process dictated in part by the abundance of cellular transcription factors that induce or repress HIV promoter activity. β-Catenin partners with members of the T cell factor (TCF)/LEF transcription factors to regulate gene expression. The interaction between β-catenin and TCF-4 is linked to inhibition of HIV replication in multiple cell types, including lymphocytes and astrocytes. Here, we evaluated the molecular mechanism by which β-catenin/TCF-4 repress HIV replication. We identified for the first time multiple TCF-4 binding sites at -336, -143, +66, and +186 relative to the transcription initiation site on the HIV long terminal repeat (LTR). Two of the sites (-143 and +66) were present in approximately 1/3 of 500 HIV-1 isolates examined. Although all four sites could bind to TCF-4, the strongest association occurred at -143. Deletion and/or mutation of -143, in conjunction with β-catenin or TCF-4 knockdown in cells stably expressing an LTR reporter construct, enhanced basal HIV promoter activity by 5-fold but had no effect on Tat-mediated transactivation of the HIV LTR. We also found that TCF-4, β-catenin, and the nuclear matrix binding protein SMAR1 tether at the -143-nucleotide (nt) site on the HIV LTR to inhibit HIV promoter activity. Collectively, these data indicate that TCF-4 and β-catenin at -143 associate with SMAR1, which likely pulls the HIV DNA segment into the nuclear matrix and away from transcriptional machinery, leading to repression of basal HIV LTR transcription. These studies point to novel avenues for regulation of HIV replication by manipulation of β-catenin signaling within cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674979      PMCID: PMC3416155          DOI: 10.1128/JVI.00486-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Nuclear matrix protein SMAR1 represses HIV-1 LTR mediated transcription through chromatin remodeling.

Authors:  Kadreppa Sreenath; Lakshminarasimhan Pavithra; Sandeep Singh; Surajit Sinha; Prasanta K Dash; Nagadenahalli B Siddappa; Udaykumar Ranga; Debashis Mitra; Samit Chattopadhyay
Journal:  Virology       Date:  2010-02-11       Impact factor: 3.616

2.  IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner.

Authors:  Wei Li; Lisa J Henderson; Eugene O Major; Lena Al-Harthi
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

3.  Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia.

Authors:  K A Thompson; J C McArthur; S L Wesselingh
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

Review 4.  HIV reservoirs: the new frontier.

Authors:  Maria D Iglesias-Ussel; Fabio Romerio
Journal:  AIDS Rev       Date:  2011 Jan-Mar       Impact factor: 2.500

5.  Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism.

Authors:  Eliseo A Eugenin; Janice E Clements; M Christine Zink; Joan W Berman
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

6.  Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes.

Authors:  Srinivas D Narasipura; Lisa J Henderson; Sidney W Fu; Liang Chen; Fatah Kashanchi; Lena Al-Harthi
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

7.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

Review 8.  Role of β-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics.

Authors:  Lisa J Henderson; Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-08       Impact factor: 4.147

Review 9.  The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis.

Authors:  Alireza Minagar; Paul Shapshak; Robert Fujimura; Ray Ownby; Melvin Heyes; Carl Eisdorfer
Journal:  J Neurol Sci       Date:  2002-10-15       Impact factor: 3.181

10.  Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia.

Authors:  Melissa J Churchill; Steven L Wesselingh; Daniel Cowley; Carlos A Pardo; Justin C McArthur; Bruce J Brew; Paul R Gorry
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

View more
  36 in total

1.  Astrocytes as an HIV CNS reservoir: highlights and reflections of an NIMH-sponsored symposium.

Authors:  Lena Al-Harti; Jeymohan Joseph; Avindra Nath
Journal:  J Neurovirol       Date:  2018-11-05       Impact factor: 2.643

2.  17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription.

Authors:  Erika L Szotek; Srinivas D Narasipura; Lena Al-Harthi
Journal:  Virology       Date:  2013-06-12       Impact factor: 3.616

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

4.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

5.  Canonical Wnts Mediate CD8+ T Cell Noncytolytic Anti-HIV-1 Activity and Correlate with HIV-1 Clinical Status.

Authors:  Jennillee Wallace; Srinivas D Narasipura; Beverly E Sha; Audrey L French; Lena Al-Harthi
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

6.  β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection.

Authors:  Yosra Aljawai; Maureen H Richards; Melanie S Seaton; Srinivas D Narasipura; Lena Al-Harthi
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

7.  Dynamic interaction between astrocytes and infiltrating PBMCs in context of neuroAIDS.

Authors:  Maureen H Richards; Srinivas D Narasipura; Stephanie Kim; Melanie S Seaton; Victoria Lutgen; Lena Al-Harthi
Journal:  Glia       Date:  2014-10-21       Impact factor: 7.452

Review 8.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

Review 9.  Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS.

Authors:  Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

10.  Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription through its intact core and cysteine-rich domains inhibits Wnt/β-catenin signaling in astrocytes: relevance to HIV neuropathogenesis.

Authors:  Lisa J Henderson; Amit Sharma; Maria Chiara G Monaco; Eugene O Major; Lena Al-Harthi
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.